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ABSTRACT
Objective: To evaluate the impact of autologous hematopoetic stem cell transplantation 
(autoHSCT) in the health related quality of life (HRQL) in patients with multiple sclerosis. 
Method: The sample consisted of 34 patients, over 18 years old, treated at a University 
Hospital in the state of São Paulo, Brazil. For data collection MOS SF-36 and EDSS scales 
were applied at three time points: admission of the patient, hospital discharge and 1 
year posttransplantation. Results: 27 patients (79%) showed stabilization or neurological 
improvement 1 year posttransplantation. At this time point, there was statistically significant 
improvement in all domains of the HRQoL. When EDSS scores were correlated with the 
domains of the MOS SF-36 scale, statistically significant correlations were found with 
physical functioning at the three time points analysed. Conclusion: In spite of the high 
risk of complications of the procedure, the HSCT had positive impact in the health related 
quality of life.
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Impacto do transplante autólogo de células-tronco hematopoéticas na qualidade de 
vida de pacientes com esclerose múltipla
RESUMO
Objetivo: Avaliar o impacto do transplante de células-tronco hematopoéticas (TCTH) 
na qualidade de vida relacionada à saúde (QVRS) de pacientes com esclerose múltipla 
(EM). Método: A amostra foi composta por 34 sujeitos, maiores de 18 anos, atendidos 
em um hospital-escola do interior do Estado de São Paulo, Brasil. Para coleta de dados 
foram aplicados os instrumentos MOS SF-36 e EDSS. Resultados: 27 (79%) sujeitos 
apresentaram estabilização ou melhora neurológica um ano após o TCTH. Decorrido 
um ano do procedimento, houve melhora estatisticamente significativa em todos os 
domínios da QVRS. Ao relacionar os escores da EDSS com os domínios do MOS SF-36, 
foram encontradas diferenças estatisticamente significantes na Funcionalidade nos três 
momentos do TCTH. Conclusão: Apesar do elevado risco de complicações, pode-se afirmar 
que o TCTH repercutiu positivamente na apreciação que o paciente faz de sua QVRS.
Palavras-chave: qualidade de vida, esclerose múltipla, transplante de medula óssea.
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In addition to the physical complications to which the 
sufferer of multiple sclerosis (MS) is subject, the psycho-
logical aspects of this disease should also be considered. 
The incidence of psychopathological disorders, especially 
depression, is high in MS and may be even higher than in 
other neurological and chronic disabling diseases. The re-
sults of some international studies suggest that up to one 
third of MS patients may have symptoms of depression1. In 
the Brazilian context the prevalence of depressive symp-
toms in MS reaches 17.9% and anxiety symptoms, 35.7%2.
Another study in 104 patients with MS showed that 
depression has a negative impact in all domains of the 
health-related quality of life (HRQoL) and anxiety has 
negative impact in mental domains3. Other studies show 
that depressive symptoms in MS correlate with fatigue4-6.
Another variable which influences the HRQoL in MS 
patients is functional disability, which is measured by the 
EDSS scale. In the literature, it was observed positive cor-
relation of depression and functional impairment and 
negative correlation between functional impairment and 
HRQoL domains measured by the MOS SF-36 scale7.
Advances in pharmacobiological therapy for system-
ic autoimmune diseases (AID) have not prevented a sub-
population of patients with progressive forms of these 
diseases, refractory to conventional therapy, having a 
poor prognosis. The low life quality and life expectancy 
of these patients justifies the use of very aggressive ther-
apies such as high dose chemotherapy, immunotherapy 
and/or radiotherapy, with or without hematopoetic stem 
cell transplantation (HSCT)8.
HSCT is essentially the replacement of defective bone 
marrow with a healthy and efficacious one9. There are 
currently various types of HSCT, the differentiator being 
the source of the progenitor cells. Autologous HSCT, the 
object of this study, is characterized by the fact that the 
donor is the patient himself, who has his cells extracted 
during the process of remission of the disease.
Autologous HSCT appears in this scenario as a prom-
ising alternative treatment for MS. It was initially pro-
posed as a treatment for this disease in the nineties10. 
Studies showed that there was a halt in the progress of 
the disease after three years in about 75% of cases of MS 
patients who underwent autologous HSCT11. 
However, despite the initial encouraging results, it 
should be noted that HSCT is not a procedure that yields 
full resolution. The immunosuppression induced by the 
preHSCT conditioning makes the patient temporarily 
vulnerable to many complications which impair his/her 
physical well being and threaten his/her life8.
Because it is an innovative therapy in the treatment 
of AID, there is an urgent need for studies that can as-
sess not only the effectiveness of the technique, but also 
its impact on patients’ lives. Most studies have been lim-
ited to the clinical approach, despite the wide recogni-
tion of the importance of also evaluating the emotional 
aspects involved when this therapy is used to treat dis-
eases such as MS.
The assessment of the quality of life construct allows 
an analysis to be made, from the perspective of the patient, 
of the impact of a disease and of the proposed treatments. 
In this context, quality of life constitutes an important in-
dicator of the ability of a chronic autoimmune disease, 
such as MS, to significantly affect the patient’s welfare12. 
As the present study is within a biomedical field, the 
concept of health-related quality of life was used, which 
can be understood as the perceived health status. This re-
fers to the perception of a person, with or without a dis-
ease, in relation to their state of health13-14.
Among the instruments used to assess HRQoL, the 
generic ones are those developed in order to reflect the 
impact of a disease on the lives of patients in a wide va-
riety of populations15. Medical Outcomes Study 36-Item 
Short-Form Health Survey (MOS SF-36) is one of the 
most used questionnaires, in a health context, through-
out the world. 
A study of HRQoL compared the performance obtained 
by patients with MS in relation to the normative popula-
tion and demonstrated an overall negative impact caused 
by the disease in all evaluated domains16. In the Brazilian 
context, the study compared HRQoL in MS patients with 
a healthy population and confirmed the hypothesis that 
the patients have impaired HRQoL in physical and psy-
chosocial domains, in relation to the healthy population17.
On study performed in Brazil18 showed that autoim-
mune diseases by themselves lead to an intense decrease 
of HRQoL in patients submitted to HSCT for those dis-
eases. In that study, pretransplant and early postrans-
plant results were compared in 19 patients submitted to 
HSCT. The evaluation indicated an improvement in the 
domain of physical functioning of HRQoL assessed by the 
MOS SF-36 scale. The improvement of some aspects of 
the HRQoL after transplantation, compared to the pre-
transplant period, was observed both in the national and 
international literature19-20.
According to the literature, the variables that may in-
fluence the HRQoL in patients with MS submitted to 
HSCT are general mental health (anxiety and depres-
sion disorders), vitality (fatigue, tiredness, exaustion), the 
EDSS score and the time from diagnosis to the procedure.
This study aims to contribute to this field of research, 
since, in both national and international literature, there 
are few studies on the quality of life of MS patients un-
dergoing HSCT therapy, due to its high complexity and 
pioneering status. 
The goal of the study was to evaluate the impact of 
the HSCT in the HRQoL of MS patients. Specifically, it 
Arq Neuropsiquiatr 2010;68(4)
524
Autologous hematopoetic stem cell transplantation: QL in MS
Guimarães et al.
evaluated the relationship between the dependent vari-
ables time, EDSS score and HRQoL domains in MS pa-
tients submitted to HSCT.
METHOD 
This is a descriptive, exploratory and clinical study, 
with longitudinal cross-section. The project was approved 
by the Ethics Committee of the Clinical Hospital, School 
of Medicine of Ribeirão Preto, University of São Paulo 
(HCFMRP No 5808/2007). 
Patients
The sample consisted of 34 patients with MS, of both 
sexes, who had undergone autologous HSCT in the Bone 
Marrow Transplant Unit (BMTU) - HCFMRP-USP, be-
tween May 2003 and May 2008. The sample represents 
85% of the study population. The selection criteria in-
cluded having MS diagnosis; having a minimum age of 18 
years; being attended on the ward and at the outpatient 
clinic of the BMTU during the period defined by the eval-
uation; presenting medical and psychological conditions; 
being willing to cooperate voluntarily with the research.
Instruments 
[1] The Medical Outcomes Study 36-Item Short-Form 
Health Survey (MOS SF-36 Health Survey)21 is a measure 
of health status designed for use in clinical practice, re-
search, health policy evaluations, and general population 
surveys. It is a multidimensional instrument for gener-
ic assessment of HRQoL, originally created in the Eng-
lish language, translated and validated for Brasil22. It con-
sists of 36 items that assess two components: the physical 
health component (PHC) and the mental health compo-
nent (MHC). The PHC comprises the domains: physical 
functioning, role limitations due to physical problems, 
bodily pain and general health perceptions. The MHC 
comprises the domains: vitality, social functioning, role 
limitations due to emotional problems and general mental 
health. The results of each domain range from 0 to 100, in 
which zero represents the worst state of health and 100 
the best state of health22.
[2] Expanded Disability Status Scale (EDSS)23: is a 
scale employed to determine functional performance 
in MS, translated and validated for the Portuguese lan-
guage24. The scale is used as a main measurement of effi-
cacy in most clinical studies of MS, albeit it overempha-
sizes mobility and is less sensitive to other dimensions of 
the disease25. EDSS values are directly proportional to the 
patient’s neurological dysfunction.
HRQoL evaluation
Data were collected at the three critical points pro-
posed for evaluation patient admission, hospital discharge 
and 1 year after transplantation. The instruments were 
applied individually in a closed environment, consider-
ing the principles of comfort and privacy of the subjects 
of the study.
The job of scoring the MOS SF-36 data was carried 
out by two judges, both psychologists with expertise 
in psychological assessment, one of them being the re-
searcher. They independently established the results and 
classified the protocols. The judges operated according to 
specific recommendations from the literature for correc-
tion of each instrument.
With the scored protocols, the data was tabulated us-
ing the database program Excel for Windows® 2007 ver-
Table 1. Numerical and percentage distribution of patients with 
multiple sclerosis undergoing stem cell transplantation, according 
to socio-demographic and clinical characteristics (n=34). Ribeirão 
Preto, Brazil, 2003-2008.
Socio-demographic and clinical variables N %
Sex
  Female 18 52.9
Age group (years)
    ≤25 
  26 a 35
  36 a 45 
    ≥46
2
7
16
9
5.9
20.6
47.1
26.4
Conjugal status
  Without partner
  With partner
13
21
38.2
61.8
Education (years)
  1 a 4
  5 a 11
    ≥12
5
15
14
14.7
44.1
41.2
Occupational situation
  Inactive
  Active
28
6
82.3
17.7
Household income (minimum wages)
  <3
  3 a 5
  >5
7
14
13
20.6
41.2
38.2
Religion
  Practicing
  Non-practicing
23
11
67.7
32.4
Length of diagnostic (years)
    ≤5 
  6 a 7
  8 a 10
    ≥11 
8
13
8
5
23.5
38.3
23.5
14.7
Clinical form of MS*
  RRMS
  PPMS
  SPMS 
7
5
22
20.6
14.7
64.7
*The clinical forms of MS: RRMS-relapsing remitting multiple sclerosis, PPMS 
primary progressive multiple sclerosis, SPMS-secondary progressive multiple 
sclerosis.
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Table 2. Comparison between time of HSCT and the MOS SF-36 domains (n=34), Ribeirão Preto, Brazil, 2003-2008.
MOS SF-36 Domains
PreHSCT × PostHSCT1 
p
PreHSCT1 × PostHSCT2
p
Post HSCT1 × PostHSCT2
p
Physical functioning 0.09 <0.01 <0.01
Role limitations due to physical problems 0.76 <0.01 <0.01
Bodily Pain 0.50 <0.01 <0.01
General health perceptions 0.12 <0.01 <0.01
Vitality 0.28 <0.01 <0.01
Social functioning 0.99 <0.01 <0.01
Role limitations due to emotional problems 0.86 0.01 0.01
General mental health 0.48 <0.01 <0.01
HSCT: hematopoietic stem cell transplantation.
sion. To achieve the objective of the study, a statistical 
analysis was used to evaluate the relationship of depen-
dent variables (time of HSCT, EDSS score, vitality, gen-
eral mental health, physical functioning) and indepen-
dent variables (other domains of HRQoL evaluated by 
the MOS SF-36 scale). In order to evaluate the differ-
ence between the results obtained in the 3 time points of 
the study, the nonparametric Friedman test for multiple 
comparison was used. To evaluate the correlations be-
tween dependent and independ variables, the nonpara-
metric Spearman correlation test was used. Significance 
levels used were p≤0.05 e p≤0.01. 
RESULTS
Table 1 displays the social-demographic and clinical 
profile of the patients included in the study.
In Table 2 the results of the MOS SF-36 scores for 
HRQoL are shown in three periods (preHSCT, postH-
SCT1 and postHSCT2).
Comparing the three time points, it is observed an 
EDSS stabilization in 16 patients (47%), reduction of 
EDSS values in 11 (32%) and increase of EDSS in 5 (15%); 
in two patients (6%), there was progression of neurolog-
ic disability in the 2nd time point followed by improve-
ment in the 3rd time point. In summary, in 27 out of 34 
patients (79%), EDSS score estabilized or reduced 1 year 
after transplantation.
Table 3 shows the correlations between EDSS values 
and the MOS SF-36 domains.
DISCUSSION 
In relation to the clinical forms of the disease, a prev-
alence of progressive forms could be seen, 80.4% in total, 
with 64.7% of patients diagnosed with the secondary pro-
gressive form (SPMS). Relapsing remitting MS (RRMS) 
appeared in 20.6% of patients who comprised the sample. 
This result is in disagreement with the results of epidemi-
ological studies and the clinical characterization of MS in 
the Brazilian context, which demonstrate a prevalence of 
RRMS26-28. This finding suggests that patients with more 
severe forms of MS are more likely and motivated to ac-
cept treatment as complex and impacting as HSCT. 
Patients with long-term MS who have lived for many 
years with the disease have suffered sharp depreciations in 
their HRQoL as a result of disease progression and have 
tried various treatments without obtaining satisfactory re-
Table 3. Correlations between EDSS values and the MOS SF-36 domains (n=34), Brazil, Ribeirão Preto, 2003-2008.
MOS SF-36 Domains
preHSCT EDSS post HSCT1 EDSS post HSCT2 EDSS 
p r p r p r
Physical functioning 0.002* –0.509 <0.001* –0.667 0.001* –0.534
Role limitations due to physical problems 0.464 0.130 0.344 –0.167 0.594 –0.095
Bodily pain 0.438 –0.137 0.288 –0.187 0.066 –0.318
General health perceptions 0.893 –0.24 0.314 –0.178 0.091 –0.294
Vitality 0.815 0.042 0.621 0.008 0.717 –0.065
Social functioning 0.732 –0.061 0.525 –0.113 0.187 –0.232
Role limitations due to emotional problems 0.686 –0.072 0.353 –0.164 0.518 –0.115
General mental health 0.493 0.122 0.697 –0.069 0.746  0.058
*p≤.01 
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sults. Probably, these patients are tired of living with lim-
itations, such as changes in vision, loss of balance, trem-
ors, weakness, changes in the rhythm of speech, memo-
ry loss, among others. This makes them more motivated 
to undergo a radical treatment such as HSCT. Transplan-
tation offers the possibility of a recovery of quality of life 
which is already highly compromised. This finding cor-
roborates the results of other studies29-30.
In the MOS SF-36 evaluation, it is observed a signif-
icant improvement in all HRQoL domains 1 year after 
transplantation (period postHSCT2) but not after hos-
pital discharge (postHSCT1).
In another Brazilian study18 comparing the results of 
the domains of HRQoL assessed by MOS SF-36, in pa-
tients with autoimmune diseases who received HSCT 
treatment, no significant differences between the pre-
HSCT and post-HSCT period (30 days after the proce-
dure) was shown. However, the authors pointed out that 
the patients demonstrated perception of improvement in 
some aspects of their HRQoL, suggesting the importance 
of research using a qualitative approach to identify subtle 
differences in the self-assessment of patients. 
The perception of improvement of HRQoL in the late 
posttransplantation period may be related to the fact that 
the patients may not face the constant possibility of disease 
progression, translated by stabilization or improvement of 
neurologic function 1 year after the procedure. This result 
may be interpreted as a positive outcome of the HSCT 
for MS, measured by the evolution of the EDSS score.
Another finding of our study is a negative correlation 
between the EDSS score and the score of physical func-
tioning of the MOS SF-36 scale in the three time points. 
This result agrees with data from the literature showing 
that the functional capacity estimated by the EDSS score 
influences the HRQoL of patients with MS31-33.
To the extent that this stressor, so characteristic of pa-
tients with MS, is alleviated and limited by HSCT treat-
ment, the possibility emerges to rethink work and family 
issues, and also to recapture some of the dreams and un-
dertake projects that had been put aside. This shows that 
patients feel more excited about the chance to be able to 
reorganize their lives and reintegrate into society18.
One factor that must be considered when referring to 
the HRQoL of patients with MS, especially in its more se-
vere forms, undergoing HSCT, is the change imposed on 
the way they live life. Patients recover HRQoL they had 
before the procedure, but not the quality of the same life. 
Perception of changes, such as greater appreciation of life, 
resignification of values and the seeking of closer and more 
satisfactory relationships being common33. Thus, from the 
patients’ perspective, the changes imposed by the trans-
plantation procedure not always have negative meaning.
When affected by a progressive and disabling disease 
like MS, patients feel that they have lost control of their 
destiny. HSCT brings relief and restores the hope of, once 
again, having their lives in their hands. Despite all the 
complications and the impact caused by this therapy, it 
could be argued that it reflects positively on the appreci-
ation patients’ have for their HRQoL.
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